Investment Rating - The investment rating for the company is "Buy" [3][5] - The market price is reported at RMB 23.01 [3] Core Views - The company has faced short-term pressure on performance due to adjustments in medical insurance and tax issues, but there is potential for industry concentration to increase, and the company continues to grow its store count and has established a strong membership system and online business [3][5][8] - The company reported total revenue of RMB 9.283 billion in 2024, a year-on-year increase of 2.23%, and a net profit attributable to shareholders of RMB 128 million, a decrease of 69.08% [3][5] - For Q1 2025, total revenue was RMB 22.94 billion, a decrease of 0.85%, with a net profit of RMB 34 million, down 35.85% year-on-year [3][5] Summary by Relevant Sections Financial Performance - The company’s total revenue for 2024 is projected at RMB 10.32 billion, with a growth rate of 11.2% [7] - The net profit for 2025 is estimated at RMB 263 million, showing a significant recovery from the previous year [7] - The earnings per share (EPS) for 2025 is projected to be RMB 1.70, with a corresponding price-to-earnings (P/E) ratio of 13.5 [5][7] Market Position and Growth Potential - The company has a stable growth in store count, reaching 5,486 stores by 2024, with a net increase of 370 stores [8] - The membership base has exceeded 26 million, with member consumption accounting for nearly 70% of total sales, providing a solid foundation for future growth [8] - The online business generated RMB 25.86 billion in revenue in 2024, representing 27.85% of total revenue, with a year-on-year growth of 19.47% [8] Industry Outlook - The overall concentration in the pharmacy retail industry is expected to increase, with the current chain rate at 57.81%, indicating room for growth towards the 70% target set for 2025 [8] - The top 100 pharmaceutical retailers accounted for 37.8% of the total retail market, suggesting significant potential for market share expansion [8]

[分析师：张帆 Table_Author] 执业证书号：S0010522070003 邮箱：zhangfan@hazq.com 相关报告 1.《业绩稳健，成套化和出口驱动未来 业绩成长》2024-04-26 [Table_StockNameRptType] 景津装备（603279） 公司点评 利润端短期承压，持续推进成套设备产业化 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-05-26 | | 570 收盘价（元） | 16.45 | | 近 12 个月最高/最低（元） | 22.46/15.02 | | 总股本（百万股） | 576.46 | | 流通股本（百万股） | 572.05 | | 流通股比例（%） | 99.24 | | 总市值（亿元） | 94.83 | | 流通市值（亿元） | 94.10 | [公司价格与沪深 Table_Chart] 300 走势比较 -40% -30% -20% -10% 0% 10% 20% 景津装备 沪深300 2.《业务稳定拓展，成套设备持续推进》 2024-08-29 3.《利润短期承压 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company reported a revenue of 916.60 billion yuan in 2024, a year-on-year decrease of 1.28%, while the net profit attributable to shareholders was 59.76 billion yuan, an increase of 12.20% [6] - In Q1 2025, the company achieved a revenue of 268.15 billion yuan, a year-on-year increase of 10.92%, and a net profit of 20.22 billion yuan, up 26.37% [6] - The company is focusing on a "5+1" industrial layout, enhancing its core engineering machinery sector while diversifying into new industries [7] - The international market revenue reached 416.87 billion yuan in 2024, accounting for 45.48% of total revenue, with a year-on-year growth of 12% [9] - The company has revised its profit forecasts for 2025-2027, expecting revenues of 1019.62 billion yuan, 1148.34 billion yuan, and 1299.70 billion yuan respectively [10] Financial Summary - For 2024, the company reported a gross margin of 22.5% and a return on equity (ROE) of 10.3%, which improved by 0.44 percentage points from 2023 [6][13] - The projected earnings per share (EPS) for 2025-2027 are 0.67 yuan, 0.83 yuan, and 1.02 yuan respectively [10][13] - The company's price-to-earnings (P/E) ratio is projected to be 12, 10, and 8 times for 2025-2027 [10][13]

Investment Rating - The report maintains an "Accumulate-A" rating for the company [1] Core Views - The company has demonstrated strong growth in revenue and net profit, with a revenue increase of 34.14% year-on-year in 2024 and a net profit increase of 548.49% [4] - The company is a leader in module shipments and has a broad layout in AI modules and solutions, particularly in the 5G sector [4][5] - The company is expanding its edge computing capabilities through industrial intelligence and AI cloud platforms [7][9] Financial Performance - In 2024, the company achieved a revenue of 185.94 billion yuan and a net profit of 5.88 billion yuan [4] - For Q1 2025, the company reported a revenue of 52.21 billion yuan and a net profit of 2.12 billion yuan, reflecting year-on-year growth of 32.05% and 286.91% respectively [4] - The company forecasts net profits of 8.52 billion yuan, 10.27 billion yuan, and 12.75 billion yuan for 2025, 2026, and 2027, representing year-on-year growth rates of 44.9%, 20.5%, and 24.1% [10] Product and Market Position - The company continues to enhance its product line in the 5G sector, maintaining a leading position in automotive applications [5][6] - The company has established a comprehensive product line for automotive applications, serving over 60 tier 1 suppliers and more than 40 vehicle manufacturers [6] - The company is actively involved in the development of AI solutions, including a large model solution launched in August 2024, which supports various applications such as intelligent Q&A and business consulting [9] Future Outlook - The company is expected to maintain growth above the industry average due to improving IoT demand and effective cost control following strategic expansion [10] - The company aims to expand its product lines in smart antennas and millimeter-wave antennas, anticipating a surge in downstream demand [9]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark within the next six months [7][18]. Core Views - The company's performance in 2024 met expectations, with a revenue of 3.924 billion yuan, a slight decrease of 0.20% year-on-year, and a net profit of 826 million yuan, a significant increase of 536.09% year-on-year [2][4]. - In Q1 2025, the company experienced a revenue decline of 11.85% year-on-year, totaling 885 million yuan, and a net profit decrease of 52.19%, amounting to 85 million yuan [2][4]. - The report emphasizes that short-term fluctuations do not alter the company's long-term growth potential, particularly as it positions itself as a unique overseas formulation commercialization platform [4][5]. Financial Performance Summary - For 2024, the company achieved a revenue of 39.24 billion yuan and a net profit of 8.26 billion yuan, with Q4 showing a revenue increase of 5.84% year-on-year [4][5]. - The report highlights a significant decline in revenue from the heparin raw material segment, down 51.61% year-on-year, while the formulation business grew by 18.30% [4][5]. - The company is expected to see net profits of 1.063 billion yuan in 2025, with growth rates of 29%, 33%, and 30% projected for the following years [5][6]. Market Opportunities - The global biosimilar market is anticipated to grow rapidly as key biological drug patents expire, presenting significant opportunities for the company [5]. - The company has made strategic acquisitions and partnerships, including the full asset acquisition of Coherus BioSciences' adalimumab biosimilar, which has already generated over 70 million yuan in sales since its launch [5][6]. - The upcoming approval of liraglutide in April 2025 is expected to convert prior investments into substantial revenue growth [4][5].

Investment Rating - The report maintains an "Accumulate-A" rating for the company [1] Core Views - The company has demonstrated strong growth in revenue and net profit, with a revenue of 185.94 billion yuan in 2024, up 34.14% year-on-year, and a net profit of 5.88 billion yuan, up 548.49% year-on-year [4] - In Q1 2025, the company achieved a revenue of 52.21 billion yuan, reflecting a year-on-year increase of 32.05%, and a net profit of 2.12 billion yuan, up 286.91% year-on-year [4] - The company continues to lead in the module shipment market and has a broad layout in AI modules and solutions [4] Summary by Sections Market Performance - As of May 5, 2025, the closing price is 71.75 yuan, with a total share capital of 2.62 billion shares and a circulating market value of 187.74 billion yuan [3] Business Development - The company is expanding its product line in the 5G module sector and maintaining a leading position in automotive applications, with a diverse range of products for over 60 tier-1 clients and 40 automotive manufacturers [6] - The company has launched the Provecta AI brand for industrial intelligence, focusing on defect detection and automation in various sectors [7] - The ODM business has seen significant growth, with revenue from the ODM segment expected to increase by over 70% year-on-year in 2024 [8] Financial Forecast and Investment Recommendations - The company is expected to maintain growth above the industry average, with projected net profits of 8.52 billion yuan, 10.27 billion yuan, and 12.75 billion yuan for 2025, 2026, and 2027 respectively, representing year-on-year growth rates of 44.9%, 20.5%, and 24.1% [10] - The earnings per share (EPS) are forecasted to be 3.26 yuan, 3.93 yuan, and 4.87 yuan for the same years, with corresponding price-to-earnings (P/E) ratios of 22.0, 18.3, and 14.7 [10]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Insights - The company focuses on three core businesses: "Perception, Connection, and Intelligent Manufacturing," targeting the new energy vehicle and digital empowerment sectors. It aims to innovate continuously based on customer needs and integrate into national strategies and industry developments [4]. - For 2024, the company is projected to achieve revenue of 11.709 billion yuan, a year-on-year increase of 13.57%, and a net profit attributable to shareholders of 1.221 billion yuan, up 21.17% year-on-year. The growth is driven by the demand for intelligent manufacturing and connection services, particularly in the AIGC application field [4][5]. - The company maintains a global leadership position in thermal management for new energy vehicles and multifunctional sensor technology, with significant revenue contributions from its sensor business [4]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are 16.275 billion yuan, 20.012 billion yuan, and 23.577 billion yuan, respectively. Corresponding net profits are expected to be 1.701 billion yuan, 2.179 billion yuan, and 2.716 billion yuan [9][11]. - The current stock price corresponds to a price-to-earnings (P/E) ratio of 25 times for 2025, 19 times for 2026, and 16 times for 2027 [9]. Business Developments - The company plans to establish a joint venture with Lika Precision to enhance its capabilities in 3D printing, focusing on SLM manufacturing technology for various applications [6][8]. - The connection business is experiencing explosive growth, particularly in domestic and overseas markets, with significant demand for optical modules [5][6]. Market Performance - The company's stock has shown a positive trend, with a notable increase in performance over the past year, reflecting strong market confidence [7].

证券研究报告 | 2025年05月26日 长青集团（002616.SZ） 优于大市 行稳致远的生物质发电龙头，携手中科系推动数字+智能转型 公司为民营生物质发电龙头企业。公司 1993 年成立，以燃气具制造业务起 家，2004 进入垃圾焚烧发电领域，2007 年进入农林生物质发电领域。2021 年公司剥离制造业务成为 A 股市场上独树一帜的以农林生物质资源化利用 为主攻方向的上市公司。截至 2024 年末，公司农林生物质发电项目业务总 装机容量 491MW，仅次于国能生物和光大绿色环保位居行业第三。 生物质发电行业：经营状况承压，补贴欠款问题亟待解决。截至 2024 年底， 全国生物质发电装机容量达到 4599 万千瓦，新增装机 185 万千瓦。但 包括南网能源、华能国际、九洲集团在内的多家上市公司均对生物质发 电资产计提了资产减值损失，我们认为这与电价补贴拖欠和原材料价格 上涨等因素有关，但长青集团却依靠精细化管理业绩实现逆势增长。 核心竞争优势：风险管控+经营效益。风险管控优势：公司从项目选址到客 户选择再到产品布局均有考量，紧密跟踪《可再生能源电价附加补助资金 管理办法》修订动态，13 个项目成功纳入国 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - In 2024, the company achieved operating revenue of 4.237 billion yuan, a year-on-year decrease of 5.69%, and a net profit attributable to the parent company of 110 million yuan, a year-on-year decrease of 62.63% [2][4] - In Q4 2024, the company reported operating revenue of 1.192 billion yuan, a year-on-year increase of 6.86%, while the net profit attributable to the parent company was 16 million yuan, a year-on-year decrease of 86.33% [2][4] - In Q1 2025, the company achieved operating revenue of 1.085 billion yuan, a year-on-year increase of 5.19%, and a net profit attributable to the parent company of 42 million yuan, a year-on-year increase of 4.67% [2][4] Summary by Sections Financial Performance - The company experienced a strategic adjustment in its brand portfolio in 2024, leading to revenue pressure and a decline in profit margins. However, the gross margin improved by 4.6 percentage points due to an ongoing optimization of brand structure, with a higher proportion of high-end brands [11] - The sales expense ratio increased by 7.7 percentage points year-on-year, attributed to increased brand promotion investments, while the management and R&D expense ratios also saw slight increases [11] - In Q4 2024, the company saw a recovery in revenue growth, with a year-on-year increase of 7%, and a gross margin improvement of 3.1 percentage points [11] - For Q1 2025, the company maintained stable revenue growth of 5%, with a gross margin increase of 2.4 percentage points, indicating effective control over brand marketing expenses [11] Future Outlook - The company aims to establish itself as a "global emerging luxury beauty group," with ongoing investments in high-end brands and market expenses. The revenue is expected to stabilize, and profit margins are anticipated to gradually recover [11] - Forecasted net profits for 2025, 2026, and 2027 are projected to be 230 million yuan, 320 million yuan, and 390 million yuan, respectively [11]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - In 2024, the company achieved a total revenue of 10.78 billion, representing a year-on-year growth of 21%, and a net profit attributable to shareholders of 1.55 billion, up 30% year-on-year. In Q4 2024, the revenue was 3.81 billion, with a growth of 4.3%, and the net profit was 550 million, growing by 23.4% year-on-year. For Q1 2025, the revenue reached 2.36 billion, a growth of 8.1%, with a net profit of 390 million, up 28.9% year-on-year [2][4]. Summary by Sections Revenue and Profit Performance - In 2024, the main brand maintained steady growth, with online and offline revenues of 10.23 billion and 530 million respectively, showing a growth of 23.7% and a decline of 13.6%. The main brand generated 8.58 billion in revenue, up 19.6% year-on-year. The company launched new products and upgraded core series during the reporting period [5][6]. Margin and Cost Management - The company's net profit margin improved by 1.0 percentage points in 2024, primarily due to a 1.5 percentage point increase in gross margin to 71.4%, attributed to lower freight rates. The sales expense ratio increased by 3.3 percentage points due to higher promotional costs, while management expenses decreased by 1.7 percentage points due to reduced share-based payment costs [6][7]. Future Growth Potential - In Q1 2025, the company demonstrated strong profit elasticity with a net profit margin increase of 2.7 percentage points to 16.5%. The gross margin rose by 2.7 percentage points to 72.8%, likely due to a decrease in major raw material costs. The company expects continued growth from its sub-brands and core series upgrades, which are anticipated to contribute to future revenue growth [7][8]. Earnings Forecast - The company forecasts EPS of 4.63, 5.40, and 6.02 yuan per share for 2025, 2026, and 2027 respectively, indicating a positive outlook for earnings growth [7].